Top

Journal of Neurology

Published in:

01-05-2019 | Multiple Sclerosis | Letter to the Editors

Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease

Authors: Stephan Richter, Bert Wagner, Elisabeth Gulowsen Celius

Published in: Journal of Neurology | Issue 5/2019

Excerpt

Dear Sirs, …

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA (2012) Investigators C-MI. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet 380:1819–1828CrossRef

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA (2012) Investigators C-MI. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829–1839CrossRef

Havrdova E, Horakova D, Kovarova I (2015) Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 8:31–45CrossRefPubMedPubMedCentral

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL (2017) Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology 89:1117–1126CrossRefPubMedPubMedCentral

Malmeström C, Andersson BA, Lycke J (2014) First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS. J Neurol 261:2016–2018CrossRefPubMed

Wertman E, Zilber N, Abramsky O (1992) An association between multiple sclerosis and type I diabetes mellitus. J Neurol 239:43–45CrossRefPubMed

Marrosu MG, Cocco E, Lai M, Spinicci G, Pischedda MP, Contu P (2002) Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet 359:1461–1465CrossRefPubMed

Hussein WI, Reddy SS (2006) Prevalence of diabetes in patients with multiple sclerosis. Diabetes Care 29:1984–1985CrossRefPubMed

Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Sondermann W, Pul R, Kleinschnitz C, Wiendl H, Meuth MD, Klotz SG (2018) L. Vitiligo after alemtuzumab treatment, Secondary autoimmunity is not all about B cells. Neurology 91:e2233–e2237CrossRefPubMedPubMedCentral

10.

Della Valle P, Coluccia A, Martinelli V, Comi G, D´Angelo A, Moiola L (2018) Acquired haemophilia a as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: a case report. Mult Scler Relat Disord 27:403–405PubMed

11.

Hoffman BM, Zeid NA, Alam U, Caress JB (2019) Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration. Mult Scler Relat Disord 27:131–132CrossRefPubMed

Title: Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease
Authors: Stephan Richter
Bert Wagner
Elisabeth Gulowsen Celius
Publication date: 01-05-2019
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Sclerosis
Lambert-Eaton Myasthenic Syndrome
Insulins
Type 1 Diabetes
Thyroiditis
Insulins
Alemtuzumab
Alemtuzumab
Published in: Journal of Neurology / Issue 5/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09257-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2019

Dissecting the neurological phenotype in children with callosal agenesis, interhemispheric cysts and malformations of cortical development

Cerebral microbleeds are associated with cognitive decline early after ischemic stroke

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis

Lifestyles correlate with stroke recurrence in Chinese inpatients with first-ever acute ischemic stroke

Effect of small-vessel disease on cognitive trajectory after atrial fibrillation-related ischaemic stroke or TIA

Congenital myasthenic syndrome caused by novel COL13A1 mutations